公开(公告)号：US20090169557A1

公开(公告)日：2009-07-02

申请号：US11579467

申请日：2005-05-10

申请人： Gordon D. Ross ,  Trunetta Jo Dockter Ross ,  Steven J. Karel ,  Daniel K. Connors ,  Bill Kournikakis

发明人： Gordon D. Ross ,  Trunetta Jo Dockter Ross ,  Steven J. Karel ,  Daniel K. Connors ,  Bill Kournikakis

IPC分类号： A61K39/395 ,  A61K31/716 ,  A61K39/00 ,  A61P31/12

CPC分类号： A61K31/716 ,  A61K39/42 ,  A61K2300/00

摘要： The present invention relates to compositions and methods of using whole glucan particles and agents. Whole glucan particles enhance the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. This binding enhances innate immune system cytotoxicity, as well as stimulating the release of activating cytokines and enhances the bodies response to the agent.

摘要翻译： 本发明涉及使用全葡聚糖颗粒和试剂的组合物和方法。 全葡聚糖颗粒通过结合C3补体蛋白受体CR3增强先天免疫系统的杀肿瘤活性。 这种结合增强先天免疫系统的细胞毒性，以及刺激激活细胞因子的释放并增强机体对药剂的反应。

公开(公告)号：US09522187B2

公开(公告)日：2016-12-20

申请号：US14528900

申请日：2014-10-30

申请人： University of Louisville Research Foundation, Inc. ,  Trunetta Jo Dockter Ross

发明人： Gordon D. Ross

IPC分类号： A61K31/715 ,  A61K31/47 ,  A61K39/395 ,  A61K31/716 ,  A61K39/00

CPC分类号： A61K31/716 ,  A61K31/47 ,  A61K31/715 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K2317/732 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

摘要： The present invention relates to methods of using neutral soluble glucan and monoclonal antibodies for antitumor therapy. Neutral soluble Beta (1,3; 1,6) glucan (NSG) enhances the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. The glucan does not stimulate the induction of inflammatory cytokines. Also described are methods of using whole glucan particles (WGP) as an immunomodulator by inducing a shift from a Th2 response to the Th1 response, leading to an enhanced antitumor cytotoxic T-cell response.

摘要翻译： 本发明涉及使用中性可溶性葡聚糖和单克隆抗体进行抗肿瘤治疗的方法。 中性可溶性β（1,3; 1,6）葡聚糖（NSG）通过结合C3补体蛋白受体CR3增强先天免疫系统的杀肿瘤活性。 葡聚糖不刺激炎性细胞因子的诱导。 还描述了通过诱导从Th2应答向Th1应答的转变来使用全葡聚糖颗粒（WGP）作为免疫调节剂的方法，导致增强的抗肿瘤细胞毒性T细胞应答。

公开(公告)号：US08883760B2

公开(公告)日：2014-11-11

申请号：US10526185

申请日：2003-09-04

申请人： Trunetta Jo Dockter Ross

发明人： Gordon D. Ross

IPC分类号： A61K31/715 ,  A61K31/47 ,  A61K39/395

CPC分类号： A61K31/716 ,  A61K31/47 ,  A61K31/715 ,  A61K39/39558 ,  A61K2039/505 ,  A61K2039/545 ,  C07K16/18 ,  C07K2317/732 ,  C07K2317/75 ,  C07K2317/76 ,  A61K2300/00

摘要： The present invention relates to methods of using neutral soluble glucan and monoclonal antibodies for antitumor therapy. Neutral soluble Beta (1,3; 1,6) glucan (NSG) enhances the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. The glucan does not stimulate the induction of inflammatory cytokines. Also described are methods of using whole glucan particles (WGP) as an immunomodulator by inducing a shift from a Th2 response to the Th1 response, leading to an enhanced antitumor cytotoxic T-cell response.

摘要翻译： 本发明涉及使用中性可溶性葡聚糖和单克隆抗体进行抗肿瘤治疗的方法。 中性可溶性β（1,3; 1,6）葡聚糖（NSG）通过结合C3补体蛋白受体CR3增强先天免疫系统的杀肿瘤活性。 葡聚糖不刺激炎性细胞因子的诱导。 还描述了通过诱导从Th2应答向Th1应答的转移来使用全葡聚糖颗粒（WGP）作为免疫调节剂的方法，导致增强的抗肿瘤细胞毒性T细胞应答。

公开(公告)号：US08563531B2

公开(公告)日：2013-10-22

申请号：US12217701

申请日：2008-07-08

申请人： Gary R. Ostroff ,  Trunetta Jo Dockter Ross

发明人： Gary R. Ostroff ,  Gordon D. Ross

IPC分类号： A01N43/04 ,  A61K31/715

CPC分类号： A61K31/715 ,  A61K31/716

摘要： The invention relates to methods for treating and preventing radiation and/or chemotherapy related injury and/or afflictions, such as myelosuppression and decreased macrophage activity, by administering a prophylactically or therapeutically effective amount of particulate, bioavailable β(1,3; 1,6) glucan. The invention also relates to methods in which β(1,3; 1,6) glucan is provided in the form of whole glucan particles, microparticulate β-glucan particles or a combination thereof.

公开(公告)号：US20100166751A1

公开(公告)日：2010-07-01

申请号：US12615040

申请日：2009-11-09

申请人： Gary R. Ostroff ,  Gordon D. Ross ,  Trunetta Jo Dockter Ross

发明人： Gary R. Ostroff ,  Gordon D. Ross ,  Trunetta Jo Dockter Ross

IPC分类号： A61K39/395 ,  C12N5/00 ,  A61P35/04

CPC分类号： A61K31/716 ,  A61K2039/505 ,  C07K16/3084

摘要： The present invention relates to methods of using whole glucan particles and complement activating antibodies for antitumor therapy. Whole glucan particles enhance the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. This binding enhances innate immune system cytotoxicity, as well as stimulating the release of activating cytokines.

摘要翻译： 本发明涉及使用全葡聚糖颗粒和补体活化抗体进行抗肿瘤治疗的方法。 全葡聚糖颗粒通过结合C3补体蛋白受体CR3增强先天免疫系统的杀肿瘤活性。 这种结合增强先天免疫系统的细胞毒性，以及刺激激活细胞因子的释放。

公开(公告)号：US20090163439A1

公开(公告)日：2009-06-25

申请号：US12217701

申请日：2008-07-08

申请人： Gary R. Ostroff ,  Gordon D. Ross ,  Trunetta Jo Dockter Ross

发明人： Gary R. Ostroff ,  Gordon D. Ross ,  Trunetta Jo Dockter Ross

IPC分类号： A61K31/716 ,  A61P39/00

CPC分类号： A61K31/715 ,  A61K31/716

摘要： The invention relates to methods for treating and preventing radiation and/or chemotherapy related injury and/or afflictions, such as myelosuppression and decreased macrophage activity, by administering a prophylactically or therapeutically effective amount of particulate, bioavailable β(1,3; 1,6) glucan. The invention also relates to methods in which β(1,3; 1,6) glucan is provided in the form of whole glucan particles, microparticulate β-glucan particles or a combination thereof.

摘要翻译： 本发明涉及通过施用预防或治疗有效量的颗粒，生物可利用的β（1,3; 1,6）来治疗和/或预防辐射和/或化学疗法相关的损伤和/或损害，例如骨髓抑制和巨噬细胞活性降低的方法 ）葡聚糖。 本发明还涉及以全葡聚糖颗粒，微粒β-葡聚糖颗粒或其组合的形式提供β（1,3; 1,6）葡聚糖的方法。